(LMAT) LeMaitre Vascular - Ratings and Ratios
Vascular Grafts, Endarterectomy Kits, Shunts, Bypass Catheters, Valvulotomes
LMAT EPS (Earnings per Share)
LMAT Revenue
Description: LMAT LeMaitre Vascular
LeMaitre Vascular Inc, listed on NASDAQ under the ticker symbol LMAT, is a US-based company operating in the Health Care Equipment sub-industry. To evaluate its performance, we need to examine key financial metrics and drivers.
The companys market capitalization stands at approximately $1.9 billion, with a price-to-earnings (P/E) ratio of 41.15 and a forward P/E of 37.31, indicating a relatively high valuation compared to its current earnings. The return on equity (RoE) is 13.53%, suggesting a decent return for shareholders. To further assess its financial health, we should consider revenue growth, profit margins, and cash flow generation.
Key economic drivers for LeMaitre Vascular include the demand for vascular surgery products and the overall growth of the healthcare industry. The companys performance is likely influenced by factors such as the prevalence of vascular diseases, advancements in medical technology, and the competitive landscape. To gauge its competitive position, we can analyze metrics such as market share, product innovation, and sales and marketing expenses as a percentage of revenue.
From a trading perspective, its essential to monitor KPIs such as trading volume, liquidity, and volatility. With an average trading volume of 117,735 shares, LMAT appears to have a reasonable level of liquidity. The stocks beta of 0.785 suggests relatively lower volatility compared to the broader market. To identify potential trading opportunities, we can analyze trends, support and resistance levels, and other technical indicators.
LMAT Stock Overview
| Market Cap in USD | 2,097m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2006-10-19 |
LMAT Stock Ratings
| Growth Rating | 44.5% |
| Fundamental | 76.6% |
| Dividend Rating | 63.8% |
| Return 12m vs S&P 500 | -11.8% |
| Analyst Rating | 3.73 of 5 |
LMAT Dividends
| Dividend Yield 12m | 0.83% |
| Yield on Cost 5y | 2.48% |
| Annual Growth 5y | 10.99% |
| Payout Consistency | 100.0% |
| Payout Ratio | 36.9% |
LMAT Growth Ratios
| Growth Correlation 3m | 70.4% |
| Growth Correlation 12m | -35.3% |
| Growth Correlation 5y | 82.9% |
| CAGR 5y | 24.49% |
| CAGR/Max DD 3y | 0.73 |
| CAGR/Mean DD 3y | 2.59 |
| Sharpe Ratio 12m | 0.60 |
| Alpha | 0.05 |
| Beta | 0.200 |
| Volatility | 33.81% |
| Current Volume | 94.3k |
| Average Volume 20d | 140.6k |
| Stop Loss | 89.3 (-3.1%) |
| Signal | -0.75 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (47.1m TTM) > 0 and > 6% of Revenue (6% = 14.1m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 0.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 170.2% (prev 91.12%; Δ 79.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 58.8m > Net Income 47.1m (YES >=105%, WARN >=100%) |
| Net Debt (158.7m) to EBITDA (72.3m) ratio: 2.19 <= 3.0 (WARN <= 3.5) |
| Current Ratio 13.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (22.9m) change vs 12m ago 0.73% (target <= -2.0% for YES) |
| Gross Margin 69.11% (prev 66.98%; Δ 2.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 49.89% (prev 56.63%; Δ -6.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 22.29 (EBITDA TTM 72.3m / Interest Expense TTM 2.79m) >= 6 (WARN >= 3) |
Altman Z'' 7.11
| (A) 0.69 = (Total Current Assets 430.1m - Total Current Liabilities 30.8m) / Total Assets 577.6m |
| (B) 0.28 = Retained Earnings (Balance) 160.8m / Total Assets 577.6m |
| (C) 0.13 = EBIT TTM 62.3m / Avg Total Assets 470.3m |
| (D) 0.74 = Book Value of Equity 158.1m / Total Liabilities 214.9m |
| Total Rating: 7.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.62
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 2.68% = 1.34 |
| 3. FCF Margin 22.30% = 5.57 |
| 4. Debt/Equity 0.47 = 2.39 |
| 5. Debt/Ebitda 2.37 = -0.71 |
| 6. ROIC - WACC (= 3.96)% = 4.95 |
| 7. RoE 13.67% = 1.14 |
| 8. Rev. Trend 95.60% = 7.17 |
| 9. EPS Trend 95.22% = 4.76 |
What is the price of LMAT shares?
Over the past week, the price has changed by -0.57%, over one month by -2.88%, over three months by +13.94% and over the past year by +4.59%.
Is LeMaitre Vascular a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LMAT is around 98.39 USD . This means that LMAT is currently overvalued and has a potential downside of 6.82%.
Is LMAT a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LMAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 104.8 | 13.8% |
| Analysts Target Price | 104.8 | 13.8% |
| ValueRay Target Price | 107.5 | 16.8% |
Last update: 2025-09-12 04:40
LMAT Fundamental Data Overview
CCE Cash And Equivalents = 319.5m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 45.1902
P/E Forward = 37.1747
P/S = 8.9377
P/B = 5.7822
P/EG = 2.1885
Beta = 0.779
Revenue TTM = 234.6m USD
EBIT TTM = 62.3m USD
EBITDA TTM = 72.3m USD
Long Term Debt = 168.2m USD (from longTermDebt, last quarter)
Short Term Debt = 2.83m USD (from shortTermDebt, last quarter)
Debt = 171.0m USD (Calculated: Short Term 2.83m + Long Term 168.2m)
Net Debt = 158.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.95b USD (2.10b + Debt 171.0m - CCE 319.5m)
Interest Coverage Ratio = 22.29 (Ebit TTM 62.3m / Interest Expense TTM 2.79m)
FCF Yield = 2.68% (FCF TTM 52.3m / Enterprise Value 1.95b)
FCF Margin = 22.30% (FCF TTM 52.3m / Revenue TTM 234.6m)
Net Margin = 20.08% (Net Income TTM 47.1m / Revenue TTM 234.6m)
Gross Margin = 69.11% ((Revenue TTM 234.6m - Cost of Revenue TTM 72.5m) / Revenue TTM)
Tobins Q-Ratio = 12.33 (Enterprise Value 1.95b / Book Value Of Equity 158.1m)
Interest Expense / Debt = 0.76% (Interest Expense 1.30m / Debt 171.0m)
Taxrate = 22.57% (12.8m / 56.9m)
NOPAT = 48.2m (EBIT 62.3m * (1 - 22.57%))
Current Ratio = 13.96 (Total Current Assets 430.1m / Total Current Liabilities 30.8m)
Debt / Equity = 0.47 (Debt 171.0m / last Quarter total Stockholder Equity 362.7m)
Debt / EBITDA = 2.37 (Net Debt 158.7m / EBITDA 72.3m)
Debt / FCF = 3.27 (Debt 171.0m / FCF TTM 52.3m)
Total Stockholder Equity = 344.7m (last 4 quarters mean)
RoA = 8.16% (Net Income 47.1m, Total Assets 577.6m )
RoE = 13.67% (Net Income TTM 47.1m / Total Stockholder Equity 344.7m)
RoCE = 12.14% (Ebit 62.3m / (Equity 344.7m + L.T.Debt 168.2m))
RoIC = 10.25% (NOPAT 48.2m / Invested Capital 470.6m)
WACC = 6.29% (E(2.10b)/V(2.27b) * Re(6.75%)) + (D(171.0m)/V(2.27b) * Rd(0.76%) * (1-Tc(0.23)))
Shares Correlation 3-Years: 87.88 | Cagr: 0.27%
Discount Rate = 6.75% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈44.1m ; Y1≈54.4m ; Y5≈92.7m
Fair Price DCF = 69.68 (DCF Value 1.58b / Shares Outstanding 22.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 95.22 | EPS CAGR: 37.49% | SUE: 1.31 | # QB: 1
Revenue Correlation: 95.60 | Revenue CAGR: 19.86% | SUE: 1.71 | # QB: 2
Additional Sources for LMAT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle